Charles River Laboratories International, Inc.
Charles River Laboratories International
CRL · NYSE
Healthcare
Catalog as of September 15, 2026. Not a live market feed.
- Fiscal Year
- 2025
- Revenue
- $4B
- Assets
- $7.1B
- SEC filing
- DEF 14A
- Filed
- March 31, 2026
Executive Compensation
Compensation reported for Charles River Laboratories International’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.
James C. Foster
Chair, President, Chief Executive Officer And Director
$15.4M
Reported total
- Salary
- $1,545,636
- Stock awards
- $11,601,089
- Incentives
- $2,182,666
- Option awards
- $0
- Other
- $105,829
Michael G. Knell
Senior Vice President, Chief Accounting Officer & Interim Chief Financial Officer Birgit Girshick Corporate Executive Vice President
$2.1M
Reported total
- Salary
- $448,118
- Stock awards
- $1,195,459
- Incentives
- $377,500
- Option awards
- $0
- Other
- $86,607
James C. Foster
Chair, President, Chief Executive Officer And Director
$15.4M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A Summary Compensation Table, filed March 31, 2026.
- Salary
- $1.5M
- Stock Awards
- $11.6M
- Incentives
- $2.2M
- Other
- $106K
Historical Compensation
James C. Foster total compensation, fiscal years 2023–2025.
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $1,545,636 | $11,601,089 | $15,435,220 |
| 2024 | $1,512,578 | $8,951,630 | $13,473,609 |
| 2023 | $1,461,866 | $9,138,724 | $14,096,924 |
Named Executive Officers
James C. Foster
Chair, President, Chief Executive Officer And Director
Charles River Laboratories International · CRL
$15.4M
FY 2025 · DEF 14A
Michael G. Knell
Senior Vice President, Chief Accounting Officer & Interim Chief Financial Officer Birgit Girshick Corporate Executive Vice President
Charles River Laboratories International · CRL
$2.1M
FY 2025 · DEF 14A
Source information
- Company
- Charles River Laboratories International, Inc.
- Ticker
- CRL · NYSE
- Filing type
- DEF 14A
- Fiscal year
- 2025
- Filing date
- March 31, 2026
- SEC accession number
- 0001104659-26-037367
Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing
Related Companies
Johnson & Johnson
JNJ · NYSE
Joaquin Duato
Chairman/CEO
$32.8M
FY 2025 reported total
View company →
UnitedHealth
UnitedHealth Group Incorporated
UNH · NYSE
Stephen Hemsley
Chief Executive Officer
$60.9M
FY 2025 reported total
View company →
AbbVie
AbbVie Inc.
ABBV · NYSE
Robert A. Michael
Chairman Of The Board And Chief Executive Officer
$32.5M
FY 2025 reported total
View company →
Abbott
Abbott Laboratories
ABT · NYSE
Robert B. Ford
Chairman Of The Board And Chief Executive Officer
$24.2M
FY 2025 reported total
View company →